Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies
Open Access
- 31 August 2015
- journal article
- research article
- Published by Taylor & Francis Ltd in OncoImmunology
- Vol. 5 (3), e1066062
- https://doi.org/10.1080/2162402x.2015.1066062
Abstract
The glucocorticoid (GC) steroid dexamethasone (Dex) is used as a supportive care co-medication for cancer patients undergoing standard care pemetrexed/platinum doublet chemotherapy. As trials for new cancer immunotherapy treatments increase in prevalence, it is important to track the immunological changes induced by co-medications commonly used in the clinic, but not specifically included in trial design or in pre-clinical models. Here, we document a number of Dex -induced immunological effects, including a large-scale lymphodepletive effect particularly affecting CD4+ T cells but also CD8+ T cells. The proportion of regulatory T cells within the CD4+ compartment did not change after Dex was administered, however a significant increase in proliferation and activation of regulatory T cells was observed. We also noted Dex -induced proportional changes in dendritic cell (DC) subtypes. We discuss these immunological effects in the context of chemoimmunotherapy strategies, and suggest a number of considerations to be taken into account when designing future studies where Dex and other GCs may be in use.Keywords
This publication has 75 references indexed in Scilit:
- Glucocorticoid receptor signaling in health and diseaseTrends in Pharmacological Sciences, 2013
- Decreased Ratio of CD8+ T Cells to Regulatory T Cells Associated with Decreased Survival in Dogs with OsteosarcomaJournal of Veterinary Internal Medicine, 2010
- Glucocorticoid-mediated Inhibition of Lck Modulates the Pattern of T Cell Receptor-induced Calcium Signals by Down-regulating Inositol 1,4,5-Trisphosphate ReceptorsOnline Journal of Public Health Informatics, 2009
- Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?Clinical Cancer Research, 2008
- Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophagesJCI Insight, 2007
- Links between innate and cognate tumor immunityCurrent Opinion in Immunology, 2007
- Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoidsAnnals Of The Rheumatic Diseases, 2006
- Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 2006
- Glucocorticoids cause rapid dissociation of a T‐cell‐receptor‐associated protein complex containing LCK and FYNEMBO Reports, 2006
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006